SARS-CoV-2感染或COVID-19疫苗接种后患者的肾活检发现
在德国单中心,对27例SARS-CoV-2疫苗接种后和15例COVID-19患者的自体肾活检进行分析,并与2019至2021年全部10206例自体肾活检对比。疫苗接种后以肾小球病为主(20/27,74%),COVID-19以急性肾小管损伤最常见。两组肾功能恢复率相似(69%与73%)。2019至2021年间坏死性肾小球肾炎、血栓性微血管病或足细胞病的频率未见增加。
要点
- 疫苗接种后肾活检以肾小球病为主(20/27,74%),坏死性肾小球肾炎占30%(8/27)。
- COVID-19患者肾活检以急性肾小管损伤最常见,血栓性微血管病仅见于COVID-19组。
- 两组肾功能恢复率相似(69%与73%),2019至2021年特定肾病频率未增加。
核心结论
- SARS-CoV-2疫苗接种后与COVID-19两组间疾病实体频率存在差异:疫苗接种后肾小球病更常见,COVID-19肾小管间质病更常见。
- 血栓性微血管病病例仅见于COVID-19组。
- 2019年至2021年间,坏死性肾小球肾炎、血栓性微血管病或足细胞病的频率未见增加。
研究设计与样本
- 在德国单中心回顾性分析自体肾活检:SARS-CoV-2疫苗接种后患者27例,COVID-19患者15例。
- 将上述诊断与2019年(大流行前)、2020年(大流行期)、2021年(疫苗接种期)全部自体肾活检(n=10,206)中的诊断进行比较。
- 临床试验注册:Kidney Histopathology After COVID-19 and SARS-CoV-2 Vaccination,NCT05043168。
主要发现
- 活检指征为血清肌酐升高和/或新发蛋白尿。
- 疫苗接种后患者中肾小球病(20/27,74%)比肾小管间质病更常见,最常见类型为坏死性肾小球肾炎(8/27,30%)、原发性足细胞病和其他肾小球肾炎类型(各6/27,22%)。
- COVID-19患者中最常见的肾脏疾病为急性肾小管损伤,其次为血栓性微血管病和坏死性肾小球肾炎。
- 疫苗接种后组与COVID-19感染组的肾功能恢复率相似(69%与73%)。
- 本中心2019年至2021年间坏死性肾小球肾炎、寡免疫肾小球肾炎、血栓性微血管病或原发性足细胞病的频率未增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Emerging case series described a temporal association between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and de novo or relapsing kidney diseases. We aimed to further understand vaccination- and coronavirus disease 2019 (COVID-19)-associated kidney diseases. METHODS: We present findings from native kidney biopsies of patients recently vaccinated against SARS-CoV-2 ( n =27) and those with COVID-19 ( n =15), reviewed at a single German center. Diagnoses were compared among all native kidney biopsies ( n =10,206) obtained between the prepandemic (2019), pandemic (2020), and vaccination periods (2021) to determine whether there was an increase in kidney diseases in the observed periods. RESULTS: Biopsy indication was increased serum creatinine and/or new-onset proteinuria. Glomerulopathies (20/27, 74%) were more common than tubulointerstitial diseases in postvaccination patients, with necrotizing GN (8/27, 30%) and primary podocytopathies and other GN types (6/27, 22% each) the most common forms. Acute tubular injury was the most common kidney disease in patients with COVID-19, followed by thrombotic microangiopathy (TMA) and necrotizing GN. The postvaccination and COVID-19 infection groups had similar kidney function recovery rates (69% and 73%, respectively). Furthermore, the frequencies of necrotizing GN, pauci-immune GN, TMA, or primary podocytopathies at our center did not increase between 2019 and 2021. CONCLUSIONS: We observed differences in entity frequencies between the SARS-CoV-2 vaccination or COVID-19 groups, with glomerulopathies being more common in patients after vaccination and tubulointerstitial diseases in patients with COVID-19. Cases of TMA were observed only in the COVID-19 group. We detected no increase in the frequency of necrotizing GN, TMA, or podocytopathies between 2019 and 2021. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Kidney Histopathology After COVID-19 and SARS-CoV-2 Vaccination, NCT05043168. PODCAST: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2023_05_08_CJN0000000000000106.mp3.
引用
- de Las Mercedes Noriega M, Husain-Syed F, Wulf S, et al. Kidney Biopsy Findings in Patients with SARS-CoV-2 Infection or After COVID-19 Vaccination. Clin J Am Soc Nephrol. 2023. PMID: 36723286. doi:10.2215/CJN.0000000000000106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。